Annual report pursuant to Section 13 and 15(d)

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.21.4
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
 12 Months Ended
Oct. 31, 2021
Oct. 31, 2020
Segment Reporting Information [Line Items]    
Net Loss $ (13,127,923) $ (10,092,363)
Total operating costs and expenses 13,648,192 9,978,202
Less non-cash share-based compensation (8,058,078) (4,137,460)
Operating costs and expenses excluding non-cash share-based compensation 5,590,114 5,840,742
Total assets 36,257,404 9,452,964
CAR-T Therapeutics [Member]    
Segment Reporting Information [Line Items]    
Net Loss (5,672,622) (2,241,443)
Operating costs and expenses excluding non-cash share-based compensation 2,421,487 1,141,542
Total assets 15,067,933 2,988,124
Cancer Vaccines [Member]    
Segment Reporting Information [Line Items]    
Net Loss (4,558,811) (828,136)
Operating costs and expenses excluding non-cash share-based compensation 1,641,977 365,681
Total assets 13,276,518 946,923
Anti-Viral Therapeutics [Member]    
Segment Reporting Information [Line Items]    
Net Loss (2,927,979) (1,168,969)
Operating costs and expenses excluding non-cash share-based compensation 1,080,279 739,140
Total assets 7,368,214 2,464,361
Cancer Diagnostics [Member]    
Segment Reporting Information [Line Items]    
Net Loss (78,067) (5,836,594)
Operating costs and expenses excluding non-cash share-based compensation 49,170 3,581,377
Total assets 391,618 2,869,529
Patent Licensing [Member]    
Segment Reporting Information [Line Items]    
Net Loss 109,556 (17,221)
Operating costs and expenses excluding non-cash share-based compensation 397,201 13,002
Total assets $ 153,121 $ 184,027